Baillie Gifford & Co
CVAC

Baillie Gifford & Co’s CureVac CVAC Stock Holding History

Baillie Gifford & Co’s Portfolio CVAC Stock Details CVAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-287,249
Closed -$3.91M – 488
2022
Q2 		$3.91M Sell
287,249
-3,624,098
-93% -$60M ﹤0.01% 247
2022
Q1 		$76.7M Sell
3,911,347
-11,993
-0.3% -$239K 0.05% 154
2021
Q4 		$135M Sell
3,923,340
-17,391
-0.4% -$700K 0.07% 132
2021
Q3 		$215M Sell
3,940,731
-1,574,531
-29% -$94.9M 0.11% 112
2021
Q2 		$405M Sell
5,515,262
-314,839
-5% -$31.5M 0.2% 99
2021
Q1 		$533M Buy
5,830,101
+1,028,445
+21% +$99.8M 0.3% 82
2020
Q4 		$389M Buy
4,801,656
+905,181
+23% +$69.3M 0.22% 86
2020
Q3 		$181M Buy
+3,896,475
New +$217M 0.12% 105

Other funds holding CVAC

GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baillie Gifford & Co's CVAC Position: Q3 2022 in Review

Baillie Gifford & Co sold out of CureVac (CVAC) in Q3 2022, closing a stake of 287,249 shares — an estimated $3.91M sold.

Baillie Gifford & Co first reported a position in CVAC in Q3 2020 and held it in 8 quarters. The position peaked at $533M in Q1 2021. 83 funds tracked by Wall St. Rank hold CVAC as of Q3 2022.

  • Baillie Gifford & Co reported no remaining CureVac position as of Q3 2022 after selling out during the quarter.
  • Baillie Gifford & Co sold 287,249 CureVac shares in Q3 2022, an estimated $3.91M.
  • Baillie Gifford & Co first reported a position in CureVac in Q3 2020 and held it in 8 quarters.
  • Baillie Gifford & Co's CureVac position peaked at $533M in Q1 2021.
  • 83 funds tracked by Wall St. Rank held CureVac as of Q3 2022.

Based on Baillie Gifford & Co's 13F filing for Q3 2022, filed 27 Oct 2022.